ATE404208T1 - Uridin-therapie für patienten mit erhöhten purin- werten - Google Patents
Uridin-therapie für patienten mit erhöhten purin- wertenInfo
- Publication number
- ATE404208T1 ATE404208T1 AT01979786T AT01979786T ATE404208T1 AT E404208 T1 ATE404208 T1 AT E404208T1 AT 01979786 T AT01979786 T AT 01979786T AT 01979786 T AT01979786 T AT 01979786T AT E404208 T1 ATE404208 T1 AT E404208T1
- Authority
- AT
- Austria
- Prior art keywords
- patients
- purine levels
- uridine
- elevated purine
- elevated
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title abstract 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045145 uridine Drugs 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/689,551 US6727231B1 (en) | 2000-10-12 | 2000-10-12 | Uridine therapy for patients with elevated purine levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404208T1 true ATE404208T1 (de) | 2008-08-15 |
Family
ID=24768963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01979786T ATE404208T1 (de) | 2000-10-12 | 2001-10-12 | Uridin-therapie für patienten mit erhöhten purin- werten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6727231B1 (de) |
| EP (1) | EP1324761B1 (de) |
| JP (1) | JP2004527460A (de) |
| AT (1) | ATE404208T1 (de) |
| AU (2) | AU2002211711B2 (de) |
| CA (1) | CA2425593A1 (de) |
| DE (1) | DE60135358D1 (de) |
| WO (1) | WO2002030354A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030294B2 (en) * | 2000-03-16 | 2011-10-04 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| US7440590B1 (en) * | 2002-05-21 | 2008-10-21 | University Of Kentucky Research Foundation | System and technique for retrieving depth information about a surface by projecting a composite image of modulated light patterns |
| US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| US20050129710A1 (en) * | 2003-10-08 | 2005-06-16 | Renshaw Perry F. | Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| EP1765075A4 (de) * | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose |
| WO2005123097A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
| WO2006020703A1 (en) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
| EP1813623B1 (de) * | 2004-09-17 | 2011-11-09 | Kissei Pharmaceutical Co., Ltd. | In der 8-stellung modifiziertes purin-nukleosidderivat und dessen medizinische verwendung |
| KR20070046185A (ko) * | 2004-09-23 | 2007-05-02 | 메르츠 파마 게엠베하 운트 코. 카가아 | 소아 행동장애의 치료를 위한 메만틴 |
| JP4778946B2 (ja) * | 2007-12-03 | 2011-09-21 | 明治飼糧株式会社 | 血中尿酸値低下剤 |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| WO2019094596A1 (en) * | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| EP4012414A1 (de) * | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnose von autismus-spektrum-störung phänotyp 1 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| IT1219667B (it) | 1988-06-21 | 1990-05-24 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
| IL108524A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Imidazodiazepine analogs |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| CA2339008C (en) * | 1998-07-31 | 2009-12-15 | Massachusetts Institute Of Technology | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US7638501B1 (en) * | 1999-02-23 | 2009-12-29 | The Regents Of The University Of California | Method of treatment of mitochondrial disorders |
-
2000
- 2000-10-12 US US09/689,551 patent/US6727231B1/en not_active Expired - Lifetime
-
2001
- 2001-10-12 AT AT01979786T patent/ATE404208T1/de not_active IP Right Cessation
- 2001-10-12 DE DE60135358T patent/DE60135358D1/de not_active Expired - Fee Related
- 2001-10-12 CA CA002425593A patent/CA2425593A1/en not_active Abandoned
- 2001-10-12 EP EP01979786A patent/EP1324761B1/de not_active Revoked
- 2001-10-12 AU AU2002211711A patent/AU2002211711B2/en not_active Ceased
- 2001-10-12 WO PCT/US2001/032051 patent/WO2002030354A2/en not_active Ceased
- 2001-10-12 AU AU1171102A patent/AU1171102A/xx active Pending
- 2001-10-12 JP JP2002533801A patent/JP2004527460A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU1171102A (en) | 2002-04-22 |
| WO2002030354A2 (en) | 2002-04-18 |
| EP1324761A4 (de) | 2004-09-08 |
| EP1324761A2 (de) | 2003-07-09 |
| WO2002030354A3 (en) | 2002-07-11 |
| EP1324761B1 (de) | 2008-08-13 |
| JP2004527460A (ja) | 2004-09-09 |
| AU2002211711B2 (en) | 2007-05-17 |
| DE60135358D1 (de) | 2008-09-25 |
| US6727231B1 (en) | 2004-04-27 |
| CA2425593A1 (en) | 2002-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE404208T1 (de) | Uridin-therapie für patienten mit erhöhten purin- werten | |
| DK1955700T3 (da) | Terapeutisk behandling af androgenreceptor-betingede lidelser | |
| AU2002366641A1 (en) | Methods for inhibiting ocular processes | |
| DE60037578D1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| BR0211986A (pt) | 29-enóis de rapamicina | |
| TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
| MY139142A (en) | Short corridor progressive addition lenses with reduced unwanted astigmatism | |
| DE50012408D1 (de) | Polyurethanlösungen mit alkoxysilanstruktureinheiten | |
| ATE394121T1 (de) | Verwendung von antikörpern gegen das muc18- antigen | |
| NO20041917D0 (no) | Spesifikke midler som binder humant angiopoietin-2 | |
| DE69910045D1 (de) | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren | |
| NO20054343L (no) | Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor | |
| IL142900A0 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
| EP1558766A4 (de) | Verwendung von a33-antigenen und jam-it | |
| EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
| YU89103A (sh) | Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a | |
| WO2004047727A3 (en) | Compositions and methods for diagnosing and treating mood disorders | |
| PT1143917E (pt) | Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico | |
| PT1092040E (pt) | Metodos de inibicao helicobacter pylori | |
| FI20040531A7 (fi) | Insuliiniresistenttien tilojen hoitaminen ja diagnosointi | |
| NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
| PT1603544E (pt) | Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina | |
| ATE418613T1 (de) | Antimikrobielle zusammensetzungen | |
| NO20060420L (no) | 2-aminobenzoylderivater | |
| PE20399A1 (es) | Muteina ob |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |